HUTCHMED to Present Promising Oncology Data at 2025 ASCO Meeting

HUTCHMED (China) ( (HK:0013) ) has provided an update.

HUTCHMED (China) Limited announced the presentation of new clinical data at the 2025 ASCO Annual Meeting, highlighting promising results from several studies involving their compounds savolitinib, ranosidenib, fruquintinib, and surufatinib. Key findings include the successful interim analysis of the SACHI Phase III study for savolitinib in combination with osimertinib, indicating improved progression-free survival in NSCLC patients, and the promising CNS activity observed in the SAVANNAH Phase II study. Additionally, the Phase I study of ranosidenib showed durable responses in solid tumor patients with IDH mutations, and the FRUSICA-1 study demonstrated meaningful efficacy of fruquintinib plus sintilimab in advanced endometrial cancer. These results underscore HUTCHMED’s potential impact on cancer treatment, reinforcing its position in the oncology market and offering significant implications for stakeholders.

The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

More about HUTCHMED (China)

HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily in the oncology sector, with a strong emphasis on innovative drug development and clinical research.

Average Trading Volume: 7,721,540

Technical Sentiment Signal: Sell

Current Market Cap: HK$18.48B

See more insights into 0013 stock on TipRanks’ Stock Analysis page.